Schizophrenia News

The incidence of cannabis use disorder associated with schizophrenia almost tripled among Canadian teenagers and adults after cannabis legalization, according to a study published in JAMA Network Open.

The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously developed drugs, according to data in a research latter published in JAMA Network Open.

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature Medicine showed.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Genetic predisposition for schizophrenia and frequent use of cannabis both independently corresponded with an increased likelihood of developing psychosis, results of a case-control study showed.

Genetically predicted major depression may present in women, but not men, with increased risk for arrhythmia disorders, coronary artery disease and heart failure, and risk may vary based on menopausal status, researchers reported.

Individuals who visited the ED for hallucinogen use had a greater risk for developing a schizophrenia spectrum disorder compared with the general population and ED visits for other substances, researchers found.

Two FDA committees overwhelmingly voted to strike down monitoring requirements under a Risk Evaluation and Mitigation Strategy, or REMS, program for clozapine, a medication for individuals with treatment-resistant schizophrenia.

Individuals with a predelivery history of concussion appeared to be at increased risk for severe maternal mental illness, highlighting the importance of screening and supportive care for this high-risk group, according to researchers.